Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease

Annals of Neurology

Volumn 75, Issue 4, 2014, Pages 574-580

  Squitti, Rosanna ^a,b   Ghidoni, Roberta ^c   Siotto, Mariacristina ^d   Ventriglia, Mariacarla ^a   Benussi, Luisa ^c   Paterlini, Anna ^c   Magri, Mariachiara ^a   Binetti, Giuliano ^c   Cassetta, Emanuele ^a   Caprara, Deborah ^a   Vernieri, Fabrizio ^e   Rossini, Paolo M ^b,f   Pasqualetti, Patrizio ^a,b  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CERULOPLASMIN; COPPER; FERRITIN; IRON; NONCERULOPLASMIN COPPER; TRANSFERRIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IRON BLOOD LEVEL; MALE; MILD COGNITIVE IMPAIRMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CERULOPLASMIN; COGNITION DISORDERS; COPPER; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PROBABILITY; RISK FACTORS;

EID: 84899935454     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24136     Document Type: Article

References (41)

1. Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007; 69: 2205-2212.
2. Palmqvist S, Hertze J, Minthon L, et al. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. PLoS One 2012; 7: e38639.
3. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
4. Hardy J, Selkoe DJ,. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
5. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273: 12817-12826.
6. Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38: 7609-7616.
7. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999; 274: 37111-37116.
8. Bush AI, Tanzi RE,. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008; 5: 421-432.
9. Squitti R, Salustri C, Siotto M, et al. Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. Int J Alzheimers Dis 2010; 2011: 231595.
10. Squitti R, Pasqualetti P, Polimanti R, et al. Metal-score as a potential non-invasive diagnostic test for Alzheimer's disease. Curr Alzheimer Res 2013; 10: 191-198.
11. Squitti R, Ghidoni R, Scrascia F, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis 2011; 23: 239-248.
12. Walshe JM,. Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 2003; 40 (pt 2): 115-121.
13. Squitti R, Polimanti R,. Copper phenotype in Alzheimer's disease: dissecting the pathway. Am J Neurodegener Dis 2013; 2: 46-56.
14. Mueller C, Schrag M, Crofton A, et al. Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J Alzheimers Dis 2012; 29: 341-350.
15. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
16. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
17. Albert M, Smith LA, Scherr PA, et al. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci 1991; 57: 167-178.
18. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
19. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274-1278.
20. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 2006; 77: 714-718.
21. Squitti R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005; 64: 1040-1046.
22. Squitti R, Bressi F, Pasqualetti P, et al. Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 2009; 72: 50-55.
23. Hixson JE, Vernier DT,. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.
24. Squitti R, Barbati G, Rossi L, et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 2006; 67: 76-82.
25. Fei M, Jianhua W,. Apolipoprotein epsilon4-allele as a significant risk factor for conversion from mild cognitive impairment to Alzheimer's disease: a meta-analysis of prospective studies. J Mol Neurosci 2013; 50: 257-263.
26. Hsiung GY, Sadovnick AD, Feldman H,. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ 2004; 171: 863-867.
27. Kester MI, Verwey NA, van Elk EJ, et al. Progression from MCI to AD: predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011; 32: 1372-1378.
28. Barabash A, Marcos A, Ancin I, et al. APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009; 30: 1254-1264.
29. Devanand DP, Pelton GH, Zamora D, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 2005; 62: 975-980.
30. Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008; 70: 191-199.
31. Monastero R, Palmer K, Qiu C, et al. Heterogeneity in risk factors for cognitive impairment, no dementia: population-based longitudinal study from the Kungsholmen Project. Am J Geriatr Psychiatry 2007; 15: 60-69.
32. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63: 2332-2340.
33. Singh I, Sagare AP, Coma M, et al. Low levels of copper disrupt brain amyloid-beta homeostasis by altering its production and clearance. Proc Natl Acad Sci U S A 2013; 110: 14771-14776.
34. Sparks DL, Schreurs BG,. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 2003; 100: 11065-11069.
35. Brewer GJ,. Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease. Biofactors 2012; 38: 107-113.
36. Bucossi S, Ventriglia M, Panetta V, et al. Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2011; 24: 175-185.
37. Schrag M, Mueller C, Zabel M, et al. Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 2013; 59: 100-110.
38. Squitti R, Simonelli I, Ventriglia M, et al. Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. J Alzheimers Dis 2014; 38: 809-822.
39. Ventriglia M, Bucossi S, Panetta V, Squitti R,. Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2012; 30: 981-984.
40. Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 2006; 63: 1085-1088.
41. Squitti R, Rossini PM, Cassetta E, et al. d-Penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002; 32: 51-59.